Hassan El Abdellaoui

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Ardea Biosciences, Inc, High Point Pharmaceuticals, LLC, Vtv Therapeutics LLC. Active years: 2010-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hassan El Abdellaoui. Retrieved from https://idiyas.com/inventor/hassan-el-abdellaoui

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 20.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 65(Granted Patents)

Location History:

Aliso Viejo, CA (US) (2010)
High-Point, NC (US) (2012)
Jamestown, NC (US) (2010 - 2015)

Company Filing History:

3 out of 63

Ardea Biosciences, Inc

patents

1 out of 50

High Point Pharmaceuticals, LLC

Years Active: 2010-2015

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9198901 - Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof (2015-12-01),

2. 8350039 - Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors (2013-01-08),

3. 8101799 - Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK (2012-01-24),

4. 7759518 - Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK (2010-07-20),

5. 7652047 - Phenylamino isothiazole carboxamidines as MEK inhibitors (2010-01-26),

Title: Innovations and Contributions of Inventor Hassan El Abdellaoui

Introduction

Hassan El Abdellaoui is a notable inventor based in Jamestown, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds for treating various medical conditions. With a total of 5 patents to his name, El Abdellaoui's work has the potential to impact the treatment of diseases such as diabetes and Alzheimer's.

Latest Patents

One of his latest patents is focused on tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. This invention provides solid compositions that can be used for treating type 1 diabetes, type 2 diabetes, or obesity. Another significant patent involves substituted isoquinoline derivatives, which serve as beta-secretase inhibitors. This invention is aimed at treating diseases related to BACE, including Alzheimer's disease, and includes pharmaceutical compositions that utilize these compounds.

Career Highlights

Throughout his career, Hassan El Abdellaoui has worked with reputable companies such as Ardea Biosciences, Inc. and VTV Therapeutics LLC. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in pharmaceutical research.

Collaborations

El Abdellaoui has collaborated with notable professionals in his field, including Andreas Maderna and Dinesh Barawkar. These collaborations have further enhanced his research and development efforts, leading to impactful inventions.

Conclusion

Hassan El Abdellaoui's contributions to the pharmaceutical industry through his innovative patents demonstrate his commitment to improving healthcare solutions. His work continues to pave the way for advancements in the treatment of critical diseases.

Profile summary based on public USPTO records.